RFL-WT: the cashflow

MyFinsight

For the year ending 2025-07-31.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-07-31
Loss (gain) on sale of property and equipment	-81
Amortization of discount on available-for-sale securities	-285
Unrealized loss (gain) on equity investments - cyclo	-5,144
Change in deferred income taxes	-165
Stock-based compensation	2,123
Gain on dtlm sale transactions	30
Trade accounts receivable	151
Interest receivable	-515
Inventory	11
Prepaid expenses and other current assets	-818
Prepaid clinical costs (current and non-current)	-112
Other receivables	273
Other assets	-28
Accounts payable and accrued expenses	-922
Other current liabilities	-67
Due to related parties	-10
Accrued expenses, noncurrent	913
Convertible notes payable	5
Other liabilities	15
Consolidated net loss	-30,643
Depreciation and amortization	288
Loss on impairment of goodwill	3,050
Realized gain on available-for-sale securities	178
Unrealized loss (gain) on convertible notes receivable, due from cyclo	-719
Net unrealized gain on investments - hedge funds	0
Realized loss on investment in equity securities	0
Loss on initial investment in day three upon acquisition	0
Realized gain on equity investments - cyclo	0
Recovery of receivables from cornerstone	0
In-process research and development expense	0
Gain on dissolution of a business	0
Equity in loss of day three	0
Credit loss expense	0
Net cash used in operating activities	-18,924
Purchase of property and equipment	4
Proceeds from sale of property and equipment	13
Purchases of available-for-sale securities	16,988
Proceeds from the sale and maturities of available-for-sale securities	80,694
Purchase of intangible assets	17
Payments for convertible notes receivable, due from cyclo	19,500
Cash paid in cyclo merger, net of cash acquired	2,709
Proceeds from hedge funds	2,547
Proceeds from day three patent sale	0
Proceeds from sales of equity securities	0
Issuance of convertible notes receivable, due from cyclo	0
Purchase of investments in cyclo	0
Issuance of convertible note receivable	0
Issuance of day three promissory notes	0
Proceeds from investments - other pharmaceuticals	0
Cash acquired in acquisition of day three, net of cash payments	0
Cash acquired in the cornerstone acquisition, net of cash payments	0
Net cash provided by (used in) investing activities	44,035
Payments for taxes related to shares withheld for employee taxes	215
Proceeds from issuance of common stock in rights offering, net of transaction costs	25,001
Proceeds from sale of rafael medical devices membership units	44
Principal payments on installment note payable	0
Purchases of treasury stock	0
Net cash provided by (used in) financing activities	24,830
Effect of exchange rate changes on cash and cash equivalents	153
Net increase (decrease) in cash and cash equivalents	50,094
Cash and cash equivalents at beginning of period	2,675
Cash and cash equivalents at end of period	52,769

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

RFL-WT: the cashflow